Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants

Jankowska, Ewa A.; Jakubaszko, J.; Cwynar, Aldona; Majda, Jacek; Ponikowska, Beata; Kustrzycka‐Kratochwil, Dorota; Reczuch, Krzysztof; Borodulin-Nadzieja, Ludmiła; Banasiak, Waldemar; Poole‐Wilson, Philip A.; Ponikowski, Piotr

doi:10.1093/eurjhf/hfn004

Cited by 61 publications

(90 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The latter is possible because hyperaldosteronism also has been shown to cause bone loss in rodents (29,30). Osteoporosis also is widely recognized as being associated with heart failure, particularly in elderly patients (31); the proposed pathophysiological mechanisms include secondary hyperparathyroidism, testosterone deficiency, and excessive inflammatory cytokine production (31)(32)(33). Nonetheless, inappropriate AVP secretion is also a hallmark of low-output cardiac failure and in these instances may contribute to bone loss.…”

Section: Discussionmentioning

confidence: 99%

Functions of vasopressin and oxytocin in bone mass regulation

Sun

Tamma

Yuen

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Prior studies show that oxytocin (Oxt) and vasopressin (Avp) have opposing actions on the skeleton exerted through high-affinity G protein-coupled receptors. We explored whether Avp and Oxtr can share their receptors in the regulation of bone formation by osteoblasts. We show that the Avp receptor 1α (Avpr1α) and the Oxt receptor (Oxtr) have opposing effects on bone mass: Oxtr −/− mice have osteopenia, and Avpr1α −/− mice display a high bone mass phenotype. More notably, this high bone mass phenotype is reversed by the deletion of Oxtr in Oxtr −/− :Avpr1α −/− doublemutant mice. However, although Oxtr is not indispensable for Avp action in inhibiting osteoblastogenesis and gene expression, Avpstimulated gene expression is inhibited when the Oxtr is deleted in Avpr1α −/− cells. In contrast, Oxt does not interact with Avprs in vivo in a model of lactation-induced bone loss in which Oxt levels are high. Immunofluorescence microscopy of isolated nucleoplasts and Western blotting and MALDI-TOF of nuclear extracts show that Avp triggers Avpr1α localization to the nucleus. Finally, a specific Avpr2 inhibitor, tolvaptan, does not affect bone formation or bone mass, suggesting that Avpr2, which primarily functions in the kidney, does not have a significant role in bone remodeling.O ver the past decade, we have described direct actions of anterior and posterior pituitary hormones on the skeleton (1-8). We have shown that these actions are exerted via G protein-coupled receptors resident on both osteoblasts and osteoclasts. We also find that the skeleton is highly sensitive to the action of posterior pituitary hormones; for example, mice haploinsufficient in oxytocin (Oxt) have osteopenic bones, but lactation is normal; lactation is impaired only in Oxt −/− mice (2). Likewise, Tshr haploinsufficient mice are completely euthyroid with normal thyroid follicles but display significant osteopenia (4). The exquisite sensitivity of the skeleton to pituitary hormones comes as no surprise, considering that the pituitary gland and the skeleton are both evolutionarily more primitive than target endocrine organs (7).Apart from the known actions of growth hormone on the skeleton, Tsh, Fsh, Acth, Oxt, and vasopressin (Avp) have all been shown to regulate the formation and/or function of both osteoblasts and osteoclasts and thus to control bone remodeling in vivo (2-4, 6-8). The two neurohypophyseal hormones Oxt and Avp have opposing functions (2, 3). Oxt stimulates and Avp inhibits osteoblast formation. Consequently, the genetic deletion of the Oxt receptor (Oxtr) and Avp receptor 1α (Avpr1α) yields opposing phenotypes, notably osteopenia in Oxtr −/− mice and high bone mass in Avpr1α −/− mice (2, 3). These findings may explain the rapid recovery of bone loss at weaning when plasma Oxt levels are high (9) and also the profound loss of bone noted in chronic hyponatremic states, such as the syndrome of inappropriate antidiuretic hormone secretion (SIADH), in which serum Avp levels are elevated (3).We find high levels of Oxtr expression on ...

show abstract

Section: Discussionmentioning

confidence: 99%

Functions of vasopressin and oxytocin in bone mass regulation

Sun

Tamma

Yuen

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…DPD has been detected in CV muscle and aorta, confirming that its distribution is not restricted to bone and dentin, as previously thought. Heart failure has been associated with disturbances affecting bone metabolism and predisposing to exacerbated bone loss 17 , and elevated levels of collagen-derived molecules belonging to the bone degradation pathway were detected in patients with CV diseases 18 . Most importantly, PYD can be increased with type I as well as type II and III collagen degradation.…”

Section: Pyridinoline and Confoundersmentioning

confidence: 99%

Biomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?

Ferraccioli

Alivernini²,

Gremese³

2013

J Rheumatol

View full text Add to dashboard Cite

“…Ayrıca SDKY'ye bağlı gelişen böbrek fonksiyon bozukluğu ve glomerüler filtrasyon hızı (GFH) düşüklüğü ile uzun süreli lup diüretiklerinin kullanımına bağlı böbreklerden kalsiyum reabsorbsiyonu engellenmekte ve hipokalsemi derinleştirebilmektedir. Bu olguların giderek artan mobilizasyon problemleri ve özellikle ev dışı fiziksel aktivitelerinin azalmış olması da, güneş ışığı bağımlı 25-hidroksivitamin D (25-OH-D) sentezinin bozulmasına yol açarak, osteoporoz gelişimini kaçınılmaz kılmaktadır (3)(4)(5)(6). Azalmış kemik mineral yoğunluğu (KMY) ile gösterilebilen ilerleyici osteoporoz sonucu olarak gelişebilen patolojik kırıklar, hali hazırda fonksiyonel kapasitesi ve mobilizasyonu kısıtlı olan SDKY hastalarının morbidite ve mortalitesinin artmasına yol açmaktadır (7)(8)(9).…”

Section: Introductionunclassified

Alterations of Serum Parathormone, Calcium, and Vitamin D Levels in End-Stage Heart Failure Cases Performed with Left Ventricular Assist Device Implantation

Öztürk¹,

Kirazlı²

2018

Tod

View full text Add to dashboard Cite

Objective: Determination of the osteoporosis susceptibility in end-stage heart failure (ESHF) cases who underwent left ventricular assist device (LVAD) implantation by examining the alterations of serum parathormone (PTH), calcium, and vitamin D levels. Materials and Methods: Records of 375 patients who underwent continuous-flow LVAD implantation with diagnosis of ESHF in our clinic were retrospectively scanned. Thirty three patients with a minimum three months of follow-up, who had complete data about serum PTH, calcium,, and pro-brain natriuretic peptide (pro-BNP) levels for pre and postoperative periods, as well as those with a bone mineral density (BMD) measurement were included in the study. In cases whose bone mineral density measurements made for lomber and hip region, for parameters that were worked with demographic data, initial and last follow-up serum values were recorded and statistical changes were examined. Furthermore, the effects of implanted LVAD type on the studied parameters were evaluated comparatively. Results: Totally 33 cases, four of female (12.1%), mean age and body mass index were found 52.7±12.0 years and 27.3±4.3 kg/m 2 . Postoperative BMD examinations revealed that 50% of cases osteoporosis and 35.7% of osteopenia. Preoperative serum PTH, calcium, 25-OH-D, osteocalcin, urea, creatinine, glomerular filtration rate, and pro-BNP concentrations were 100.9±39.5 pg/mL, Lomber ve kalça bölgesi için KMY ölçümleri yapılan olguların demografik verileri ile birlikte çalışılan parametreler için başlangıç ve son takipteki serum değerleri kayıtlanmış ve istatistiksel olarak değişimleri incelenmiştir. Ayrıca implante edilen SVDC tipinin çalışılan parametreler üzerindeki etkileri karşılaştırmalı olarak değerlendirilmiştir. Bulgular: Çalışmaya alınan dördü kadın (%12,1) toplam 33 olgunun yaş ve vücut kitle indeksi ortalamaları sırasıyla 52,7±12,0 yıl ve 27,3±4,3 kg/m 2 olarak saptandı. Cerrahi sonrası alınan KMY ölçümlerine göre %50 olguda osteoporoz ve %35,7 olguda osteopeni saptandı. Olguların preoperatif serum PTH, kalsiyum, 25-OH-D, osteokalsin, üre, kreatinin, glomerüler filtrasyon hızı ve pro-BNP konsantrasyonları sırasıyla 100,9±39,5 pg/mL, 8,9±0,8 mg/dL, 26,7±17,4 ng/mL, 6,98±5,46 ng/mL, 80,2±57,9 mg/dL, 1,48±0,89 mg/dL, 52,99±13,32 mL/ dakika/1,73 m 2 ve 9348,7±8176,7 pg/mL olarak bulunurken; 14,2±7,7 aylık ortalama takip dönemi sonunda bu değerler sırasıyla 78,3±26,3 pg/mL, 9,2±0,5 mg/dL, 29,8±13,8 ng/mL, 7,55±3,14 ng/mL, 36,2±17,2 mg/dL, 0,98±0,26 mg/dL, 59,72±1,21 mL/dakika/1,73 m 2 ve 1838,9±1853,2 pg/mL olarak saptandı (sırasıyla p<0,001, p=0,033, p=0,038, p=0,841, p<0,001, p=0,003, p=0,006 ve p<0,001). Farklı iki SVDC tipi implante edilen olgular çalışma parametrelerindeki değişim açısından kıyaslandığında istatistiksel anlamlı bir fark saptanmadı. Sonuç: Sol ventriküler destek cihazı uygulanan SDKY olgularında serum kalsiyum, 25-OH-D ve PTH düzeylerinin yakın kontrolü gerekli olup, KMY ölçümlerine göre osteoporoz veya osteopeni saptananlara günlük kalsiyumdan zengin diyet öne...

show abstract

Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants

Cited by 61 publications

References 50 publications

Functions of vasopressin and oxytocin in bone mass regulation

Functions of vasopressin and oxytocin in bone mass regulation

Biomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?

Alterations of Serum Parathormone, Calcium, and Vitamin D Levels in End-Stage Heart Failure Cases Performed with Left Ventricular Assist Device Implantation

Contact Info

Product

Resources

About